Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial

医学 结直肠癌 内科学 肿瘤科 叶酸 化疗 阶段(地层学) 辅助治疗 CD8型 癌症 胃肠病学 免疫系统 免疫学 生物 古生物学
作者
Christopher Williams,Richard Gray,Robert K. Hills,Michael Shires,Liping Zhang,Zuo Zhao,Tracie Gardner,Nancy Sapanara,Xiaomeng Xu,Isaac Bai,Dongyao Yan,Andrea Murányi,Sarah Dance,Faranak Aghaei,Gemma Hemmings,Michael Hale,Uday Kurkure,Christoph Guetter,Susan D. Richman,Gordon Hutchins,Jenny F. Seligmann,Nicholas P. West,Shalini Singh,Kandavel Shanmugam,Philip Quirke
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
标识
DOI:10.1200/jco.23.02030
摘要

PURPOSE High densities of tumor infiltrating CD3 and CD8 T-cells are associated with superior prognosis in colorectal cancer (CRC). Their value as predictors of benefit from adjuvant chemotherapy is uncertain. PATIENTS AND METHODS Tumor tissue from 868 patients in the QUASAR trial (adjuvant fluorouracil/folinic acid v observation in stage II/III CRC) was analyzed by CD3 and CD8 immunohistochemistry. Pathologists, assisted by artificial intelligence, calculated CD3 and CD8 cell densities (cells/mm 2 ) in the core tumor (CT) and invasive margin (IM). Participants were randomly partitioned into training and validation sets. The primary outcome was recurrence-free interval (RFI), 2-year RFI for assessment of biomarker-treatment interactions. Maximum-likelihood methods identified optimal high-risk/low-risk group cutpoints in the training set. Prognostic analyses were repeated in the validation set. RESULTS In the training set, the recurrence rate in the high-risk group was twice that in the low-risk group for all measures (CD3-CT: rate ratio [RR], 2.00, P = .0008; CD3-IM: 2.38, P < .00001; CD8-CT: 2.17, P = .0001; CD8-IM: 2.13, P = .0001). This was closely replicated in the validation set (RR, 1.96, 1.79, 1.72, 1.72, respectively). In multivariate analyses, prognostic effects were similar in colon and rectal cancers, and in stage II and III disease. Proportional reductions in recurrence with adjuvant chemotherapy were of similar magnitude in the high- and low-recurrence risk groups. Combining information from CD3-IM and CD3-CT (CD3 Score) generated high-, intermediate-, and low-risk groups with numbers needed to treat (NNTs) to prevent one disease recurrence being 11, 21, and 36, respectively. CONCLUSION Recurrence rates in the high-risk CD3/CD8 groups are twice those in the low-risk groups. Proportional reductions with chemotherapy are similar, allowing NNTs derived in QUASAR to be updated using contemporary, nonrandomized data sets.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
3秒前
leng给leng的求助进行了留言
3秒前
杨婷婷发布了新的文献求助10
4秒前
xy完成签到 ,获得积分10
5秒前
大模型应助Zinsky采纳,获得20
5秒前
NeXt_best完成签到,获得积分10
6秒前
幸运狗子发布了新的文献求助10
6秒前
cahcah关注了科研通微信公众号
6秒前
6秒前
吉他平方发布了新的文献求助10
6秒前
8秒前
estate发布了新的文献求助10
9秒前
11秒前
jiangjiang完成签到,获得积分10
11秒前
Akim应助颜曼曦采纳,获得10
11秒前
12秒前
lala发布了新的文献求助10
13秒前
eric完成签到,获得积分10
13秒前
幸福的秋烟完成签到,获得积分10
14秒前
14秒前
yiteng完成签到,获得积分20
14秒前
14秒前
无花果应助杨婷婷采纳,获得10
15秒前
15秒前
田様应助安静的映萱采纳,获得10
15秒前
16秒前
18秒前
王晓风发布了新的文献求助10
18秒前
18秒前
18秒前
rita_sun1969发布了新的文献求助30
19秒前
风云发布了新的文献求助10
19秒前
Tingshuo发布了新的文献求助10
19秒前
20秒前
Fhy完成签到,获得积分10
20秒前
星星轨迹发布了新的文献求助10
21秒前
00000完成签到,获得积分20
22秒前
22秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3223053
求助须知:如何正确求助?哪些是违规求助? 2871842
关于积分的说明 8177183
捐赠科研通 2538719
什么是DOI,文献DOI怎么找? 1370752
科研通“疑难数据库(出版商)”最低求助积分说明 645870
邀请新用户注册赠送积分活动 619832